iPremom raises €15M seed to predict pregnancy complications early

Valencia’s iPremom has raised a €15 million seed round led by Amadeus Capital Partners, with Asabys Partners and APEX Ventures, to validate MaiRa, a blood test that predicts preeclampsia and other pregnancy complications from the first trimester.

Obstetrics still screens for its most dangerous complications largely the way it did a generation ago – blood pressure cuffs, urine strips and a lot of waiting. And yet one of the larger European health seeds of the year has just gone to a Valencia team convinced the answer was sitting in maternal blood all along. Below, I lay out the round, the science it is buying, and why the size of this seed is the more interesting story this week.

Three funds behind one first-trimester test

iPremom announced the €15 million seed round on 2 September. Amadeus Capital Partners led, with Asabys Partners and APEX Ventures participating – a London lead writing into Valencia, alongside a Barcelona health specialist and a Vienna deep-tech fund. That geography is worth pausing on: three countries on the cap table of a Spanish seed is still the exception in Europe, not the rule.

The money goes to completing the clinical validation study of MaiRa, the company’s diagnostic platform, rolling it out commercially, and preparing regulatory approvals in both the EU and the US, per the company’s announcement.

The stated ambition is blunt: catch preeclampsia, pre-term birth, fetal growth restriction and gestational diabetes months before symptoms, from a standard blood draw taken at 9 to 14 weeks of pregnancy.

Ten thousand pregnancies behind MaiRa

Founded in 2019, iPremom was built around the work of Professor Carlos Simón, the reproductive medicine researcher who co-founded the company and chairs it, with Guillermo Ferrando Huertas as CEO and Dr Tamara Garrido as chief scientific officer.

MaiRa analyses cell-free RNA circulating in maternal blood – molecular signals the company links to decidualisation resistance, a dysfunction of the uterine lining it identifies as an upstream driver of complications that today get diagnosed only when they arrive. The platform was developed on more than 26,000 samples from 10,000 pregnancies collected through the PREMOM study, which the company describes as Spain’s largest prospective clinical trial.

“Pregnancy complications have been under-diagnosed and under-treated for generations, because the field was looking in the wrong place at the wrong time,” Simón said in the announcement.

Preeclampsia alone affects 5 to 8 percent of pregnancies globally, per the company’s figures, and pregnancy complications drive some 260,000 maternal deaths a year worldwide.

A slow market waiting for a better signal

The market iPremom sells into looks modest on paper. Global preeclampsia diagnostics were worth USD 1.29 billion in 2025 and are forecast to reach USD 1.75 billion by 2035, a 3.1 percent CAGR (Precedence Research, June 2026).

So why does a diagnostics seed need €15 million against a market growing at 3 percent? Because that figure prices the current standard of care – cheap, decades-old tests that mostly confirm a complication already under way. A first-trimester predictive test is not competing for a slice of that market; it is a bet that earlier detection expands the category entirely, the way non-invasive prenatal testing did for chromosomal screening over the past decade. The good news is that the bet is at least being made with unusually deep clinical data for a seed-stage company.

Our fundraising data puts the round in context. The same week, our records logged Full Health Medical’s €3 million seed in Dublin and Holifya’s €1.6 million round in Milan – both health companies, both a fraction of this size.

The week European seeds split in two

That gap is the pattern worth watching. European seed rounds are bifurcating: the median health seed still buys a pilot and eighteen months of runway, while science-heavy companies with clinical datasets are raising seeds sized like a Series A. INLEAP Photonics’ €20 million seed for laser drone defence, covered here this week, fits the same shape – as did a London imaging startup’s $220 million raise at the other end of the pipeline.

What we are seeing is capital concentrating behind defensible science rather than spreading across software-shaped bets, and it changes what a seed round is supposed to buy: not product-market fit, but clinical validation and a regulatory dossier on two continents.

Spain is quietly a beneficiary. A Valencia diagnostics company pulling a London lead and a Vienna fund into a €15 million seed would have been a curiosity five years ago. This week it reads as the system working – deep university science, a national-scale clinical study, and cross-border capital arriving at the right stage.

Watch two things from here: whether the validation study holds up MaiRa’s first-trimester claims, and whether the US regulatory path moves before the EU one. Either way, Europe’s maternal health bench just got its reference round. The opportunity is clear.